“We are happy to use our years of experience and state of the art capacity to help grow Medeor’s program and meet its needs for clinical supply.”
MEMPHIS, Tenn. (PRWEB) May 31, 2018
Cognate BioServices, a leading contract development and manufacturing organization in the global cellular therapies industry, today announced an agreement with Medeor Therapeutics, a California biotechnology company, to manufacture MDR-102, a proprietary, organ donor-derived cellular immunotherapy product candidate for certain kidney transplant recipients.
Headquartered in Memphis, Tenn., and with a successful track record manufacturing products for innovative, therapeutic drugs in oncology and regenerative medicine on behalf of a diverse range of global clients and partners, Cognate is one of the only CDMOs capable of managing large scale personalized cellular therapy products that are being approved by regulators today. The company recently opened up new manufacturing capacity to support products for both the E.U. and the U.S. in Memphis, and is well on its way to supporting commercial scale production.
“We are very excited to be forming a relationship with the leading company in the stem cell therapeutic space for organ rejection,” said J. Kelly Ganjei, CEO of Cognate BioSerivces. “We are happy to use our years of experience and state of the art capacity to help grow Medeor’s program and meet its needs for clinical supply."
About Cognate BioServices
Cognate BioServices is a fully-integrated contract bioservices organization providing the highest level of scientific and management expertise. Cognate provides full development and cGMP manufacturing services to companies and institutions engaged in the development and manufacture of cell-based products. The combination of highly experienced staff, successful track records and cGMP facilities makes Cognate one of the most qualified contract manufacturers of cell-based products in the world today.